ELOVL2 Double Nickase Plasmid (h): sc-404998-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ELOVL2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ELOVL2 Double Nickase Plasmid (h) and ELOVL2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ELOVL2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ELOVL2 Double Nickase Plasmid (h) | sc-404998-NIC | 20 µg | $410.00 | |||
ELOVL2 Double Nickase Plasmid (h2) | sc-404998-NIC-2 | 20 µg | $410.00 |
ELOVL2 (elongation of very long chain fatty acids protein 2) is an endoplasmic reticulum–localized fatty acid elongase that catalyzes rate-limiting elongation steps producing long-chain polyunsaturated fatty acids, including precursors for DHA biosynthesis. By shaping membrane phospholipid composition and lipid-derived signaling mediators, ELOVL2 influences cellular processes such as membrane fluidity, oxidative stress responses, and metabolic homeostasis. Altered ELOVL2 activity and regulation have been associated with age-related changes in lipid metabolism and epigenetic state, and have been studied in contexts including retinal biology, neurobiology, and metabolic disease mechanisms. As a conserved node in lipid elongation pathways, ELOVL2 provides a tractable target for dissecting how PUFA availability impacts organelle function and cellular signaling networks.
ELOVL2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ELOVL2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ELOVL2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ELOVL2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ELOVL2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.